Physical exercise and non-insulin glucose-lowering therapies in the management of Type 2 diabetes mellitus: a clinical review.
Max L EcksteinD M WilliamsL K O'NeilJ HayesJ W StephensR M BrackenPublished in: Diabetic medicine : a journal of the British Diabetic Association (2018)
In the UK the National Institute of Health and Care Excellence (NICE) advocates intensive lifestyle programmes that attain the levels of daily physical activity set out by the Chief Medical Officer as a first-line strategy for improving the health of people at risk of developing diabetes or reducing the risk of development of Type 2 diabetes. For people with Type 2 diabetes, lifestyle measures complement pharmacological treatments that include both oral and injectable therapies. In line with this, NICE guidelines also support intensification of efforts to improve patient lifestyle along with these glucose-lowering therapies. There is a paucity of evidence, however, in the available published literature examining the association between glucose-lowering therapies and exercise metabolism. In the present review we explore the current knowledge with regard to the potential interactions of oral and non-insulin injectable therapies with physical activity in people at risk of, or who have, Type 2 diabetes, and present evidence that may inform healthcare professionals of the need to monitor patients more closely in their adaptation to both pharmacological therapy and physical activity.
Keyphrases
- physical activity
- type diabetes
- healthcare
- glycemic control
- cardiovascular disease
- blood glucose
- public health
- metabolic syndrome
- body mass index
- mental health
- quality improvement
- weight loss
- end stage renal disease
- systematic review
- newly diagnosed
- insulin resistance
- prognostic factors
- health information
- ejection fraction
- adipose tissue
- human health
- chronic kidney disease
- high intensity
- hyaluronic acid
- peritoneal dialysis
- cross sectional
- randomized controlled trial
- blood pressure
- climate change
- mesenchymal stem cells
- smoking cessation